Connect with us

Published

on

Anadolu | Anadolu | Getty Images

Jan Leike, one of the lead safety researchers at OpenAI who resigned from the artificial intelligence company earlier this month, said on Tuesday that he has joined rival AI startup Anthropic.

Leike announced his resignation from OpenAI early on May 15, days before the company dissolved the superalignment group that he co-led. That team, formed in 2023, focused on long-term AI risks. OpenAI co-founder Ilya Sutskever announced his departure in a post on X on May 14.

“I’m excited to join @AnthropicAI to continue the superalignment mission,” Leike wrote on X on Tuesday. “My new team will work on scalable oversight, weak-to-strong generalization, and automated alignment research.”

Anthropic is backed by Amazon, which has committed up to $4 billion in funding for a minority stake in the company.

In a post following his departure from OpenAI, Leike wrote, “Stepping away from this job has been one of the hardest things I have ever done, because we urgently need to figure out how to steer and control AI systems much smarter than us.”

AI safety has gained rapid importance across the tech sector since OpenAI introduced ChatGPT in late 2022, ushering in a boom in generative AI products and investments. Some in the industry have expressed concern that companies are moving too quickly in releasing powerful AI products to the public without adequately considering potential societal harm.

Microsoft-backed Open AI said Tuesday that it created a new safety and security committee led by senior executives, including CEO Sam Altman. The committee will recommend “safety and security decisions for OpenAI projects and operations” to the company’s board.

Anthropic, founded in 2021 by siblings Dario Amodei and Daniela Amodei and other ex-OpenAI executives, launched its ChatGPT rival Claude 3 in March. The company has received funding from Google, Salesforce and Zoom, in addition to funding from Amazon.

WATCH: Anthropic co-founder on AI adoption

Anthropic Co-Founder Daniela Amodei on AI adoption, Claude 3 and impact on payments

Continue Reading

Technology

Hims & Hers stock falls 10% on revenue miss

Published

on

By

Hims & Hers stock falls 10% on revenue miss

The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. 

Gabby Jones | Bloomberg | Getty Images

Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Earnings per share: 17 cents adjusted vs. 15 cents
  • Revenue: $544.8 million vs. $552 million

Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.

For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million.

Read more CNBC tech news

Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.

Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It’s legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. 

In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.

Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount.

Hims & Hers will host its quarterly call with investors at 5 p.m. ET.

Stock Chart IconStock chart icon

hide content

YTD chart of Hims & Hers Health.

–CNBC’s Annika Kim Constantino contributed to this report

Continue Reading

Technology

Palantir tops $1 billion in revenue for the first time, boosts guidance

Published

on

By

Palantir tops  billion in revenue for the first time, boosts guidance

Palantir reports $1 billion in revenue for the first time

Palantir topped Wall Street’s estimates Monday, surpassing $1 billion in quarterly revenue for the first time, and hiking its full-year guidance.

Shares rallied more than 5%.

Here’s how the company did versus LSEG estimates:

  • Earnings per share: 16 cents adj. vs. 14 cents expected
  • Revenue: $1.00 billion vs. $940 million expected

The artificial intelligence software provider’s revenues grew 48% during the period. Analysts hadn’t expected the $1 billion revenue benchmark from the Denver-based company until the fourth quarter of this year.

“The growth rate of our business has accelerated radically, after years of investment on our part and derision by some,” wrote CEO Alex Karp in a letter to shareholders. “The skeptics are admittedly fewer now, having been defanged and bent into a kind of submission.”

The software analytics company also boosted its full-year outlook guidance. For the full year, Palantir now expects revenues to range between $4.142 billion and $4.150 billion, up from prior guidance of $3.89 billion to $3.90 billion.

Read more CNBC tech news

For the third quarter, Palantir forecast revenues between $1.083 billion and $1.087 billion, beating an analyst estimate of $983 million. Palantir also lifted its operating income and full-year free cash flow guidance.

Palantir’s U.S. revenues jumped 68% from a year ago to $733 million, while U.S. commercial revenues nearly doubled from a year ago to $306 million.

The software analytics company has seen a boost from President Donald Trump‘s government efficiency campaign, which included layoffs and contract cuts. Palantir’s U.S. government revenues jumped 53% from the year-ago period to $426 million.

“It has been a steep and upward climb — an ascent that is a reflection of the remarkable confluence of the arrival of language models, the chips necessary to power them, and our software infrastructure,” Karp wrote in a letter to shareholders.

During the quarter, Palantir said it closed 66 deals of at least $5 million and 42 deals totaling at least $10 million. Total value of its contracts grew 140% from last year to $2.27 billion.

Net income rose 144% to about $326.7 million, or 13 cents a share, from about $134.1 million, or 6 cents per share a year ago.

Palantir shares have more than doubled this year as investors bet on the company’s AI tools and contract agreements with governments.

Its market value has accelerated past $379 billion and into the list of top 20 most valuable U.S companies, surpassing SalesforceIBM and Cisco to join the top 10 U.S. tech companies by market cap. Shares hit a new high Monday.

At its size, buying the stock requires investors to pay hefty multiples.

Shares currently trade 276 times forward earnings, according to FactSet. Tesla is the only other top 20 with a triple-digit ratio at 177.

Stock Chart IconStock chart icon

hide content

Palantir one-day stock chart.

Continue Reading

Technology

Firefly Aerospace lifts IPO range that would value company at more than $6 billion

Published

on

By

Firefly Aerospace lifts IPO range that would value company at more than  billion

Firefly Aerospace CEO Jason Kim sits for an interview at the Firefly Aerospace mission operations center in Leander, Texas, on July 9, 2025.

Sergio Flores | Reuters

Firefly Aerospace has lifted the share price range for its upcoming initial public offering in a move that would value the space technology company at more than $6 billion.

The lunar lander and rocket maker said in a filing Monday that it expects to price shares in its upcoming IPO between $41 and $43 apiece.

Firefly’s new target range would raise nearly $697 million at the top end of the range. That’s up from the previously expected $35 to $39 price per share that Firefly announced in a filing last week, which targeted a $5.5 billion valuation.

Firefly announced plans to go public last month as interest in space technology gains steam, and billionaire-led companies such as Elon Musk‘s SpaceX rake in more funding.

Read more CNBC tech news

The industry has also begun testing the public markets after a long hiatus in IPO deal activity, with space tech firm Voyager debuting in June.

Firefly makes rockets, space tugs and lunar landers, and is widely known for its satellite launching rockets known as Alpha.

The company has partnered with major defense players such as Lockheed Martin, L3Harris and NASA, and received a $50 million investment from defense contractor Northrop Grumman.

Firefly’s revenues jumped from $8.3 million a year ago to $55.9 million at the end of March, the company said. Its net loss grew to $60.1 million, from $52.8 million a year ago.

Don’t miss these insights from CNBC PRO

Firefly's ambitious plan to become the next SpaceX

Continue Reading

Trending